Skip to main content
. 2020 Aug 1;12(8):2137. doi: 10.3390/cancers12082137

Figure 6.

Figure 6

The combination treatment of ABT263 and THZ1 elicits anti-glioma activity in patient-derived xenograft model of human GBM. (a) GBM12 cells were implanted into the subcutis of immunocompromised Nu/Nu mice. Four randomly treatment groups—vehicle, ABT263 (75 mg/kg), THZ1 (10 mg/kg), and a combination of both—were assigned once the tumors were established. Mice were treated three times per week. Shown are the tumor volumes over time; (b) The graph shows tumor volume on the last day of the experiment in (a) (n = 7–10); (c) GBM43 cells were implanted into the subcutis of immunocompromised Nu/Nu mice. Four randomly treatment groups, vehicle, ABT263 (75 mg/kg), THZ1 (10 mg/kg), and the combination treatment of both, were assigned once the tumors were established. Mice were treated three times per week. Shown are the tumor volumes over time; (d) The graph shows tumor volume on the last day of the experiment in (c) (n = 9); (e–g) Tumors from the experiment in (a) were fixed and stained with H&E, TUNEL or Ki67. Shown are means and SD. ANOVA was used for statistical analysis. * p < 0.05, *** p < 0.001. Scale bar: 50 µm.